Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents (3 to <18 years) with Developmental and Epileptic Encephalopathy (BELIEVE 1)

X
Trial Profile

Open Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents (3 to <18 years) with Developmental and Epileptic Encephalopathy (BELIEVE 1)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BELIEVE; BELIEVE 1
  • Sponsors Zynerba Pharmaceuticals
  • Most Recent Events

    • 07 Sep 2021 According to a Zynerba Pharmaceuticals media release, the company announces publication of results in the Journal of the American Medical Association (JAMA) Network Open under the article titled "Safety and tolerability of transdermal cannabidiol gel in children with developmental and epileptic encephalopathies: A nonrandomized controlled trial"
    • 07 Sep 2021 Results published in the Zynerba Pharmaceuticals Media Release
    • 11 Jun 2021 According to a Zynerba Pharmaceuticals media release, data poster presented at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top